CN114269753A - 一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途 - Google Patents

一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途 Download PDF

Info

Publication number
CN114269753A
CN114269753A CN202080055686.8A CN202080055686A CN114269753A CN 114269753 A CN114269753 A CN 114269753A CN 202080055686 A CN202080055686 A CN 202080055686A CN 114269753 A CN114269753 A CN 114269753A
Authority
CN
China
Prior art keywords
membered
compound
radical
cycloalkyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080055686.8A
Other languages
English (en)
Other versions
CN114269753B (zh
Inventor
游泽金
何云
田强
宋宏梅
薛彤彤
王晶翼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Original Assignee
Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Kelun Biotech Biopharmaceutical Co Ltd filed Critical Sichuan Kelun Biotech Biopharmaceutical Co Ltd
Publication of CN114269753A publication Critical patent/CN114269753A/zh
Application granted granted Critical
Publication of CN114269753B publication Critical patent/CN114269753B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

本发明属于药物化学领域，涉及一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途。具体而言，本发明提供了一种具有式II结构的化合物，其具有显著的NLRP3调节作用，可以作为高效的NLRP3调节剂，具有抗肿瘤活性。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN202080055686.8A 2019-09-29 2020-07-31 一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途 Active CN114269753B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910932795 2019-09-29
CN2019109327952 2019-09-29
PCT/CN2020/106080 WO2021057256A1 (zh) 2019-09-29 2020-07-31 一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途

Publications (2)

Publication Number Publication Date
CN114269753A true CN114269753A (zh) 2022-04-01
CN114269753B CN114269753B (zh) 2024-03-05

Family

ID=75165544

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080055686.8A Active CN114269753B (zh) 2019-09-29 2020-07-31 一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途

Country Status (2)

Country Link
CN (1) CN114269753B (zh)
WO (1) WO2021057256A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080377A1 (ja) * 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
CN104936963A (zh) * 2012-11-20 2015-09-23 Ktb肿瘤研究有限责任公司 作为蛋白激酶抑制剂的硫醚衍生物
CN105492446A (zh) * 2013-07-30 2016-04-13 爱尔兰詹森科学公司 用于治疗病毒性感染的噻吩并[3,2-d]嘧啶衍生物
CN113195469A (zh) * 2019-02-19 2021-07-30 四川科伦博泰生物医药股份有限公司 含氮并环化合物、其制备方法及用途
CN114555565A (zh) * 2019-12-13 2022-05-27 四川科伦博泰生物医药股份有限公司 含氮并环化合物、其制备方法及用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1280580A (zh) * 1997-11-11 2001-01-17 辉瑞产品公司 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物
UA77303C2 (en) * 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
CL2003002287A1 (es) * 2002-11-25 2005-01-14 Wyeth Corp COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS
GB0412467D0 (en) * 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
TW201906838A (zh) * 2017-06-21 2019-02-16 日商第一三共股份有限公司 Ｅｐ３００／ｃｒｅｂｂｐ抑制劑

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080377A1 (ja) * 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
EP1724268A1 (en) * 2004-02-20 2006-11-22 Kirin Beer Kabushiki Kaisha Compound having tgf-beta inhibitory activity and pharmaceutical composition containing same
CN104936963A (zh) * 2012-11-20 2015-09-23 Ktb肿瘤研究有限责任公司 作为蛋白激酶抑制剂的硫醚衍生物
CN105492446A (zh) * 2013-07-30 2016-04-13 爱尔兰詹森科学公司 用于治疗病毒性感染的噻吩并[3,2-d]嘧啶衍生物
CN113195469A (zh) * 2019-02-19 2021-07-30 四川科伦博泰生物医药股份有限公司 含氮并环化合物、其制备方法及用途
CN114555565A (zh) * 2019-12-13 2022-05-27 四川科伦博泰生物医药股份有限公司 含氮并环化合物、其制备方法及用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GONZALEZ CABRERA, DIEGO等: "Structure-Activity Relationship Studies of Orally Active Antimalarial 2,4-Diamino-thienopyrimidines", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 58, no. 18, pages 7572 - 7579, XP055488177, DOI: 10.1021/acs.jmedchem.5b01156 *
JANG, MI-YEON等: "Synthesis of novel 5-amino-thiazolo[4,5-d]pyrimidines as E. coli and S.aureus SecA inhibitors", 《BIOORGANIC & MEDICINAL CHEMISTRY》, vol. 19, no. 1, pages 702 - 714, XP027577807 *
STN REGISTRY: "2285561-66-0", 《STN REGISTRY》, pages 1 *

Also Published As

Publication number Publication date
WO2021057256A1 (zh) 2021-04-01
CN114269753B (zh) 2024-03-05

Similar Documents

Publication Publication Date Title
TWI676619B (zh) 溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑
CN110156786B (zh) 嘧啶并环化合物及其制备方法和应用
CN108623615B (zh) 吡唑[3,4-d]嘧啶-3-酮的大环衍生物、其药物组合物及应用
CN104837829B (zh) 抑制剂化合物
JP2022523981A (ja) 抗癌剤として有用な縮合三環式化合物
CN113637005A (zh) 用于癌症治疗的kras抑制剂
TWI695838B (zh) 作爲ｐｄｅ１抑制劑之咪唑並吡酮
CN110573501A (zh) Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
CN112088157A (zh) 作为磷脂酰肌醇磷酸激酶抑制剂的芳基-联吡啶胺衍生物
CN111936484A (zh) 作为磷脂酰肌醇磷酸激酶抑制剂的色烯并吡啶衍生物
CN113454086A (zh) 作为tlr7激动剂的咪唑并[2,1-f][1,2,4]三嗪-4-胺衍生物
CN117062816A (zh) 三环-酰胺-双环prmt5抑制剂
CN113195469A (zh) 含氮并环化合物、其制备方法及用途
CN114075190A (zh) 杂环类btk抑制剂
KR20220140710A (ko) 트리아졸로피리다진 유도체, 이의 제조 방법, 약물 조성물 및 용도
JP2022523477A (ja) ピロロピリミジン誘導体及びこれを有効成分として含有するタンパク質キナーゼ関連疾患の予防又は治療用薬学的組成物
CN110655520A (zh) 嘧啶并环化合物及其制备方法和应用
CN114409656B (zh) Pim激酶抑制剂
CN114072393A (zh) 作为mrgx2抑制剂的3-氨基-4h-苯并[e][1,2,4]噻二嗪1,1-二氧化物衍生物
CN113490668A (zh) 用于治疗与apj受体活性有关的疾病的化合物和组合物
CN112469722A (zh) 作为a2a受体拮抗剂的吡唑并***并嘧啶衍生物
CN114805311A (zh) 螺环茚
CN109790160B (zh) 吡啶并五元芳香环类化合物、其制备方法及用途
CN115536660A (zh) 苄氨基取代的杂多环化合物及其组合物、制剂和用途
CN114269753B (zh) 一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant